As glucagon-like peptide-1 receptor agonists (GLP-1 RAs) — such as semaglutide (Ozempic, Wegovy) — gain traction for treating diabetes and promoting weight loss, a new concern is emerging: Are older adults at risk of losing too much muscle? An editorial in Annals of Internal Medicine warns that these popular drugs may exacerbate sarcopenia — the […]
